# US 2025/0146004 A1 · Materials and Methods for Treatment of Human Genetic Diseases Including Hemoglobinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146004 A1
- Document ID: US20250146004A1
- Status: Published application
- Kind: A1
- Application number: 18/769,239
- Filed: 2024-07-10
- Published: 2025-05-08
- Earliest claimed: 2015-02-23
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Matthew Hebden Porteus
- Web page: https://patentgrep.com/patent/US20250146004A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 7/06: Antianaemics
- C12N 15/09: Recombinant DNA-technology
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/10: Type of nucleic acid
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and β-thalassemia.

## Claims

### Claim 1

A method of increasing the level of fetal hemoglobin (HbF) in a human cell by genome editing, the method comprising introducing Cas9 endonuclease, a first guide RNA (gRNA), and a second gRNA into a human cell to effect a pair of double-strand breaks (DSBs) within the S8-globin region of human chromosome 11, wherein the first gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, the second gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, wherein the first gRNA hybridizes to a different target sequence than the second gRNA, wherein the editing results in increased expression of γ-globin, thereby increasing the level of HbF in the cell.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the method comprises introducing into the cell one or more polynucleotides encoding the Cas9 endonuclease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises introducing into the cell one or more RNAs encoding the Cas9 endonuclease.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein both guide RNAs are single-molecule guide RNAs.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the human cell is an isolated progenitor cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the isolated progenitor cell is a hematopoietic progenitor cell.

### Claim at position 10

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein there is a deletion of the chromosomal DNA between the pair of DSBs within the δβ-globin region of human chromosome 11.

### Claim at position 12

15-28. (canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the human cell is from a patient with a β-hemoglobinopathy which is a sickle cell disease or a β-thalassemia.

### Claim 30 (depends on 1)

The method of claim 1, wherein all or a portion of the β-globin gene is deleted.

### Claim 31 (depends on 30)

The method of claim 30, wherein the β-hemoglobinopathy is sickle cell anemia, and wherein the level of sickle cell hemoglobin (HbS) in the cell is reduced.

### Claim 32 (depends on 30)

The method of claim 30, wherein the β-hemoglobinopathy is a β-thalassemia and wherein the level of unpaired alpha hemoglobin chains in the cell is reduced.

### Claim at position 17

33-47. (canceled)

### Claim 48 (depends on 1)

The human cell produced by a method of claim 1.

### Claim 49 (depends on 48)

The human cell of claim 48, wherein the human cell is an isolated progenitor cell.

### Claim 50 (depends on 49)

The human cell of claim 49, wherein the isolated progenitor cell is a hematopoietic progenitor cell.

### Claim 51 (depends on 50)

The human cell of claim 50, wherein the hematopoietic progenitor is a cell of the erythroid lineage.

### Claim 52

(canceled)

### Claim 53 (depends on 48)

A method of ameliorating a β-hemoglobinopathy in human patient comprising administering to such patient the cell of claim 48.

### Claim 54 (depends on 53)

The method of claim 53, wherein the β-hemoglobinopathy is sickle cell disease or β-thalassemia.

### Claim at position 25

55-71. (canceled)

### Claim 72 (depends on 1)

The method of claim 1, wherein:
(a) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 4 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 19; or
(b) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 4 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 20; or
(c) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 83 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 43; or
(d) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 83 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 15; or
(e) the first gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 4 and the second gRNA comprises a spacer sequence that is complementary to SEQ ID NO: 15.

### Claim 73 (depends on 1)

The method of claim 1, wherein the first gRNA and/or the second gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NOs: 4, 5, 6, 15, 19, and 20.

### Claim 74

A method of ameliorating a β-hemoglobinopathy in human patient comprising administering to such patient a human cell, wherein the human cell has been modified by introducing into the cell Cas9 endonuclease, a first guide RNA (gRNA), and a second gRNA to effect a pair of double-strand breaks (DSBs) within the δβ-globin region of human chromosome 11, wherein the first gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, the second gRNA comprises a spacer sequence that hybridizes to the same target sequence of the δβ-globin region of human chromosome 11 as a nucleic acid having the nucleic acid sequence of any one of SEQ ID NO: 1-117 and 129-137, wherein the first gRNA hybridizes to a different target sequence than the second gRNA, wherein the editing results in increased expression of HbF in the cell.
